Astellas Pharma Inc. has seen various business developments per these news pieces, marking significant advancements in the bio-pharmaceutical sector. The company recently saw several FDA approvals, including those for its
gastric cancer therapies, digitiva for
heart failure management , and combination therapy for bladder cancer. The company also entered a significant
$2.2 bn gene therapy deal with AviadoBio Ltd and launched new Life Science Centers in Cambridge, Massachusetts and the South San Francisco Biotech Corridor, aiming to accelerate breakthrough therapies discovery. Astellas continues to focus on
Oncology, with innovative strides in cancer treatments. However, the company faced controversy as an employee was indicted by China's prosecutors. Moreover, a shift in the financial results definition was seen. Other developments include strategic collaborations with Mass General Brigham and Yaskawa, plans for a new facility in Cambridge Crossing Neighborhood, receipt of CHMP opinion, and the initiation a clinical trial of Fezolinetant for VMS in women with breast cancer.
Astellas Pharma Inc. News Analytics from Mon, 11 Oct 2021 07:00:00 GMT to Mon, 21 Oct 2024 13:32:54 GMT -
Rating 7
- Innovation 8
- Information 6
- Rumor -5
